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The hormone adrenomedullin has both physiological and pathological roles in biology.  As a potent 
vasodilator, adrenomedullin is critically important in regulation of blood pressure, but it also has 
several roles in disease, of which its actions in cancer are becoming recognized to have clinical 
importance.  Reduced circulating adrenomedullin causes increased blood pressure but also 
reduces tumor progression, so drugs blocking all effects of adrenomedullin would be unacceptable 
clinically.  However, there are two distinct receptors for adrenomedullin, each comprising the same 
G protein-coupled receptor (GPCR), the calcitonin receptor-like receptor (CLR), together with a 
different accessory protein known as a receptor activity-modifying protein (RAMP). CLR with 
RAMP2 forms an adrenomedullin-1 receptor and CLR with RAMP3 forms an adrenomedullin-2 
receptor.  Recent research suggests that selective blockade of adrenomedullin-2 receptors would 
be a valuable therapeutically.  Here we describe the design, synthesis and characterization of 
potent small molecule adrenomedullin-2 receptor antagonists with 1,000-fold selectivity over the 
adrenomedullin-1 receptor, although retaining activity against the CGRP receptor. These 
molecules have clear effects on markers of pancreatic cancer progression in vitro, drug-like 
pharmacokinetic properties and inhibit xenograft tumor growth and extend life in a mouse model of 
pancreatic cancer.  Taken together, our data support the promise of a new class of anti-cancer 
therapeutics as well as improved understanding of the pharmacology of the adrenomedullin 








Development of new therapeutic agents requires insights into the fundamental biology of target 
systems and ability to modulate the target in disease without causing deleterious off-target effects 
elsewhere. Adrenomedullin (AM) is a potent vasodilator which acts to control blood pressure by 
regulating functions including vasomotor tone 1 and glomerular filtration rate 2. Soon after the 
discovery of the hormone, profound increases in circulating AM were shown to be associated with 
catastrophic low blood pressure in patients with sepsis, who suffered consequent reduced organ 
perfusion and, in many instances, death 3-5. AM is also expressed by most tumors 6, leading to 
high serum AM levels 7 in patients. AM-mediated actions include increased tumor growth and 
markers of tumor progression 8 as well as being implicated in metastatic spread 9. As a target in 
cancer, AM is therefore compromised because reduction in circulating levels or blockade of all its 
actions would cause hypertension. However, there are two receptors for AM, each a heteromeric 
complex of the calcitonin receptor-like receptor (CLR, a Family B GPCR) to which ligand 
selectivity is conferred by association with one of the 3 human receptor activity-modifying proteins 
(RAMPs) 10, 11 (Figure 1a). While RAMPs have previously been studied primarily in context of 
Family B GPCRs, RAMPs have also been shown to have coevolved with many other GPCR 
families 12, 13. All three CLR/RAMP complexes have distinct pharmacological and physiological 
properties which are driven by the subtype of RAMP with which CLR interacts 14. Specifically, the 
CLR/RAMP1 heteromer is a receptor for calcitonin gene-related peptide (CGRP), a neuropeptide 
implicated in pain sensing 14 and small molecule antagonists of the CGRP receptor have been the 
subject of considerable research 15-17. The CLR with RAMP2 forms an AM1 receptor while the 
CLR with RAMP3 forms an AM2 receptor 11, 14, 18. While the AM1 receptor is essential for 
physiological processes including cardiovascular health 19, aberrant AM2 receptor signalling can 
result in cancer-promoting pathways 7, 20-24. In the AM receptors, despite the relatively modest 






Figure 1: Cellular role of CLR and RAMP complexes and their interactions with small 
molecules (a) Interaction of CLR receptor with a different RAMP leads to three CLR/RAMP 
receptor complexes with distinct pharmacological and physiological properties. (b) Models of 
CLR/RAMP complexes with 1 (telcagepant), based on crystal structures of CGRP and AM1 
receptors (PDB code: 3N7R and 3AQF respectively). CLR is rendered in yellow and RAMP in cyan 
in each of CLR/RAMP1 (B1), CLR/RAMP2 (B2), CLR/RAMP3 (B3). RAMP residues (at 1 binding 
site) that differ across RAMP1/RAMP2/RAMP3 are highlighted and labelled. (c) In order to design 





relatively conserved whereas the RAMP binding motifs (red) were used as scaffolds for basic 
groups to interact with Glu residues on RAMP3. 
In gene knockout mouse studies, deletion of the gene for the AM ligand leads to intrauterine 
death at mid-gestation, due to a vascular and lymphatic phenotype known as hydrops fetalis 25. 
That phenotype is copied exactly by deletion of the CLR, which prevents the formation of both 
AM1 and AM2 receptors 26.  Interestingly though, RAMP2 null mice have the same phenotype 27, 
with the same embryonic lethality and even heterozygotes exhibit significant pathology due to 
haploid insufficiency. In stark contrast, RAMP3 null mice are viable and healthy and even have 
some advantageous phenotypic characteristics 19 some of which may be replicated in humans 
with single nucleotide polymorphisms in RAMP3 28. Knockout experiments in mice are hard to 
interpret with precision as RAMPs interact not only with CLR but a number of other receptors 
including calcitonin receptors (CTR) where heteromers are amylin receptors. However, until very 
recently, no agonists or antagonists were available that provided  useful discrimination between 
RAMP2 and RAMP329. 
The published crystal structures of CLR/RAMP1 (CGRP receptor) and CLR/RAMP2 (AM1 
receptor) heteromers bound to truncated peptide antagonists CGRP27-37 and AM25-52 respectively, 
give insights into association of ligands with CLR/RAMP receptors 30, 31. A hydrophobic patch and 
a pocket that are separated by the CLR Trp72 shelf (Trp72 bulge) 30, 31 are established features.  
The hydrophobic patch is a region of aromatic residues in CLR: Trp72, Phe92, Phe95 and Tyr124 
30. The pocket is larger and incorporates residues of both components: Asp70, Trp72, Gly71, 
Trp121, Thr122 and Tyr124 of CLR with Trp74, Trp84 and Pro85 in RAMP1 or Arg97, Glu101, 
Glu105, Phe111 Pro112 in RAMP2 30. Trp84 in RAMP1 corresponds to the same position as 
Glu101 in RAMP2. Both residues were previously identified as key residues for CGRP 32 and AM 
33 function. These data suggest the presence of a β-turn on both CGRP and AM peptides that 
enables them to occupy their respective binding pockets and modulates interactions with CLR 
and RAMP residues. More specifically, via its Phe37 phenyl ring, CGRP interacts with CLR 





makes only one critical contact with RAMP1 extracellular domain (at residue Trp84) which also 
includes a hydrophobic interaction with CLR residue Phe37 30. Hydrogen bonds are formed 
between CGRP residue Val32 and the Trp72 bulge of CLR and a main-chain to side-chain 
connection is made between CGRP Thr30 and CLR loop 3 Asp94 residues 30.  
 
Similarly, AM residues Tyr52 and Lys46 interact with residues Arg97, Glu101 and Glu105 on 
RAMP2 30. An extension of a single helical turn allows AM Lys46 to contact the Trp72 bulge and 
AM Pro43 and Ala42 to interact with the patch 30. The equivalent residue on RAMP1 (Trp74) is 
unable to interact with AM 30. This was explained by absence of a Glu residue at position 74 of 
RAMP1 that discourages AM interaction 30. The importance of residues Glu101 and Phe111 on 
RAMP2 was previously shown through mutagenesis studies 33. Recent studies, including the 
recently published cryo-EM structures of the whole CGRP, AM1 and AM2 receptors, have given a 
deeper understanding to these receptor complexes and their mechanisms of activation 34-36.   
Small-molecule CGRP receptor antagonists (olcegepant, telcagepant, MK-3207, ubrogepant and 
rimegepant) have been developed 37. Some have reached the clinic, notably ubrogepant 
(Ubrelvy, NCT02828020) and rimegepant (Nurtec ODT, NCT03461757). This indicates the 
potential for developing selective antagonists for other CLR/RAMP heteromers (the AM1 and AM2 
receptors) by exploiting the key residue differences between RAMPs 38-42. Structural relationship 
studies within the gepant family of CGRP receptor antagonists have identified the presence of 
three important interactive regions in CLR/RAMP heteromers within the CGRP receptor 
antagonists – the CLR binding region, the interface region that binds close to the Trp72 bulge and 
the CLR/RAMP1 binding region that interacts with the CLR/RAMP-1 hydrophobic patch – that 
facilitate their binding and selectivity 43. 
While previous efforts to manipulate AM receptor function have been to target isolated 
components of the system – the AM ligand or receptor components (CLR, RAMP2 or RAMP3) – 





specifically target AM signalling through AM2 receptor. Recently, small molecule positive allosteric 
modulators against CLR-based receptor complexes have been identified, which are not active on 
other class B GPCRs including the closely related CTR 44.  Our approach enables AM to continue 
physiological signalling through AM1 receptors, decreasing possibilities of side effects resulting 
from this therapeutic strategy. AM and RAMP3 have been shown to mediate pro-tumoral 
processes in various cancers 7, 20-23, including pancreatic cancer 24, 45. A recent publication has 
also shown the involvement of AM/RAMP3 system (but not AM/RAMP2) in liver metastasis of 
pancreatic cancer through modification of cancer-associated fibroblasts 45. Since pancreatic 
cancer is currently an unmet clinical need for life-extending therapy, we have selected that as a 
therapeutic target.  
Results and discussion 
Design of potent selective small molecule AM2 receptor antagonists 
As CGRP, AM1 and AM2 receptors comprise the same CLR component but a different RAMP, we 
envisaged that improvements in potency and selectivity towards AM2 receptors would be gained 
by exploiting and optimizing specific interactions with RAMP3 that would be unlikely to be 
replicated with RAMP1 or RAMP2. In order to design analogues with increased potency against 
the AM2 receptor, we inspected the sequences of RAMPs 1, 2 and 3 and their relationship to the 
binding site for the known small-molecule CGRP receptor antagonists. 
Figure 1B1 shows the published structure 30 of telcagepant 1 (green) – a CGRP receptor 
antagonist – crystallized in the extracellular domains of the CLR (yellow) / RAMP1 (cyan) 
heteromer (PDB code: 3N7R). Figures 1B2 and 1B3 show the same structure (1) with RAMP2 
and RAMP3 residues changes respectively highlighted. The RAMP3 amino acid residues which 
differ from the RAMP1 sequence at the small molecule antagonist binding site are highlighted, 
specifically Glu74 (Trp in RAMP1), Thr70 (Ala in RAMP1) and Glu67 (Arg in RAMP1). We 
hypothesized that the acidic glutamate residues, which are present in RAMP3 but not RAMP1 





Furthermore, while Glu74 is common to RAMP2, that protein has a large Arg residue at position 
70, which effectively occludes the small molecule antagonist binding site as it exists in 
CLR/RAMP1 or CLR/RAMP3 receptors. We surmised that introduction of basic centres to small 
molecule CGRP antagonists could improve interactions with glutamate residues in RAMP3 (AM2 
receptor) without an expectation of potent interactions with RAMP2 (AM1 receptor). 
The majority of CGRP receptor small molecule antagonists showed minimal or no activity against 
AM1 and AM2 receptors37. However, a search of the literature highlighted two CGRP receptor 
antagonists with encouraging activity against AM2 receptor – compounds 3 (MK-3207) 46 and 2 47 
(pIC50 = 6.20 and 5.97 respectively for AM2 receptor respectively, determined in house). 
Comparison with the chemical structure of the more selective CGRP antagonist telcagepant (1) 
allowed us to highlight areas of each molecule which bind to CLR (blue) and RAMP (red) proteins 
(Figure 1c). In the CGRP receptor antagonist field, the CLR binding motifs have been relatively 
conserved. That led us to the idea that the close relationship between the CGRP and AM2 
receptors and the combination of these well-established CLR-binders with a head group designed 
to maximize preferential binding to RAMP3 over both RAMP1 and RAMP2 could deliver AM2 
receptor-preferring molecules. To this end, we targeted the red portions in Figure 1c as scaffolds 
for basic groups to interact with the glutamyl residues on RAMP3. 
Identification of small molecule AM2 receptor selective/potent antagonists 
Beginning with 2 (pIC50 = 5.97 for AM2 and 7.77 for CGRP receptors, Figure 2a), introduction of 
the CLR binding motif from 3 afforded compound 5 (pIC50 = 6.55 for AM2 and 8.31 for CGRP 
receptors, Figure 2a) which showed an increase in potency at both AM2 and CGRP receptors. 
Introduction of a benzylic amine into 2 afforded 4 (pIC50 = 6.44 for AM2 and 6.57 for CGRP 
receptors, Figure 2a) which showed a similar improvement in potency at AM2 receptor as 5 
relative to 2 but balanced activity against CGRP receptor. A combination of these changes led to 
6 (pIC50 = 8.31 for AM2 and 8.09 for CGRP receptors, Figure 2a) and gave the first dramatic 





to the discovery of 7 (pIC50 = 9.16 for AM2 and 8.38 for CGRP receptors, Figure 2a). Compound 7 
is the first highly potent and selective AM2 receptor small molecule antagonist, providing a 1000-
fold increase in potency relative to commercially available CGRP antagonists (such as 3). Further 
analysis showed significant pharmacological differences between the two enantiomeric forms of 7 
(racemate), with compound 8 ((R)-enantiomer, pIC50 = 9.21 for AM2 and 9.07 for CGRP 
receptors, Figure 2a) showing higher affinity than the (S)-enantiomer (9, pIC50 = 7.16 for AM2 and 
7.09 for CGRP receptors, Figure 2a). These hits were then screened against the AM1 receptor. 
As we predicted, lead compounds showed significant selectivity (more than 100-fold) for AM2 and 
CGRP receptors over the AM1 receptor (Figure 2a). This selectivity was maintained for other 
members of the calcitonin family of receptors (CTR, AMY1 and AMY3, Figure 2b, Figure S1 and 
Table S3). We believe the activity profile of our compounds is consistent with the proposed 
unfavourable steric clash with Arg70 of RAMP2 with tolerance of the conformationally flexible 
benzylic amine by the CGRP receptor through either ionic interaction with Asp71 or exposure to 
solvent. To determine if AM2 receptor antagonists was able to inhibit AM-induced cAMP 
production in native cells, 7 and its enantiomers (8 and 9) were tested in a human pancreatic 
cancer cell line CFPAC-1. Similar to results in the over-expressing cell lines (Figure 2a), 7 (pIC50 
= 9.33, Figure 2c) and its (R)-enantiomer (8, pIC50 = 8.96, Figure 2c) were able to inhibit AM-
induced cAMP production 100-fold more potently than its (S)-enantiomer (9, pIC50 = 7.02, Figure 
2c). In addition to their effect in human cells, AM2 receptor antagonists were able to inhibit AM-
induced cAMP production in other species including mouse and dog (Figure S2). Additionally, 
lead compounds were tested in a mouse cell line (178-2 BMA cells) to determine the potential 
effect of AM2 receptor antagonists on host cells in an in vivo tumor model. Interestingly, the 
activity of lead compounds on mouse cells were 2- to 100-fold less than in human cells (Figure 
2c). Modelling showed no obvious residue differences at the key binding site in RAMP3 between 
the species, however subtle conformational variations may be the cause of observed differences 







Figure 2: Activity and selectivity of early lead compound 6, current lead compound 7 and its 
enantiomers (8 and 9) in CLR/RAMP overexpressing and native (human and mouse) cell 
lines. (a) Primary screening was performed by measuring the ability of small molecules in inhibiting 
cAMP production in cell lines over-expressing each receptor complex. Early lead compound 6 was 
equipotent in inhibiting both CGRP and AM2 receptors. Current lead compound 7 racemate was 
the first small molecule antagonist with even modest selectivity for AM2 receptor over CGRP 
receptor (the difference was significant and 7-10-fold). (R)-enantiomer 8 is 100-fold more potent in 
inhibiting cAMP in both CGRP and AM2 receptors, compared to (S)-enantiomer 9. Lead compounds 
are significantly more selective for CGRP and AM2 receptors over other members of the calcitonin 
family of receptors (AM1, AMY1 and AMY3 receptors). Data are from at least three independent 
experiments and presented as mean±SEM. Curves are representative and do not include all data 
points (b) Graphical representation of results in (a). (c) Activity of current lead compound 7 and its 
enantiomers (8 and 9) in inhibiting AM-induced cAMP production were also tested in human 
pancreatic cancer cell line CFPAC-1 and mouse prostate cancer cell line 178-2 BMA. The activity 
of lead compounds on human CFPAC-1 cells were similar to that in overexpressing cells (a, b), 
whereas the activity on mouse 178-2 BMA were 2- to 100-fold less. ap<0.05 by unpaired t-test 





AM2 receptor antagonists showed ADME properties suitable for further optimization as 
drug-like molecules 
In vitro studies on 7 and the more potent single enantiomer 8 were performed in order to 
characterize their ADME and physicochemical properties (Table 1). Compounds 7 and 8 were 
determined to be moderately lipophilic with logD7.4 of 1.58 and 1.59, respectively and possessed 
low aqueous solubility at pH 7.4 between 86.3  and 199 µM. Intrinsic clearance (CLint) via 
metabolism measured in liver microsomes from human (21-22 µl/min/mg protein), rat (14-16 
µl/min/mg protein) and mouse (22 µl/min/mg protein) was at a level low enough to support the 
use of the compounds in further in vivo pharmacokinetic and efficacy studies. Scaling of human 
liver microsomes CLint of 8 using the well-stirred model of hepatic metabolic clearance48, 49 
predicted blood CL of 4.7 ml/min/kg in human, a relatively low fraction of hepatic blood flow (21 
ml/min/kg). Compounds 7 and 8 displayed moderate binding to plasma proteins with unbound 
fractions of 17.6% in rat (7 and 8), 8.7% in mouse (7) and 22.9 (7) and 28.6 (8) in human. The 
results of these early ADME screening data indicate that compounds 7 and 8 are suitable lead 
compounds for further optimisation as potential drug molecules. 
The inhibition profiles of 7 and 8 against several cytochrome P450 enzymes (CYPs) were also 
determined (Table 1). Both compounds were inhibitors of CYPs 2D6 (IC50 of 7 = 3.64 µM; 8 = 
1.60 µM) and 3A4 (IC50 of 7 = 2.35 µM; 8 = 7.3 µM) but were less potent against 1A2 (IC50 >50 
µM), 2C9 (IC50 of 7 = 34.15 µM; 8 > 50 µM) and 2C19 (IC50 of 7 = 26.19 µM; 8 >50µM). These 
data show that compounds 7 and 8 possess modest potency as inhibitors of major drug-
metabolising CYPs and that this chemical series is capable of being optimised for low risk of 
interaction with drugs metabolised by CYPs. Both compounds were also assessed for inhibition of 
hERG potassium channel currents as a routine indicator of risk of cardiac arrhythmia resulting 
from hERG inhibition 50. Both were found to have IC50 >30 µM, indicating low risk. 
The pharmacokinetic characteristics of 7 and 8 in rodents were examined following intravenous 





(2.66 mg/kg) and 8 (2.0 mg/kg) was similar, and high in relation to hepatic blood flow at 73.6 
ml/min/kg (7) and 62.6 ml/min/kg (8). The moderate to high volume of distribution of 7 (8.0 L/kg) 
and 8 (16.8 L/kg) resulted in terminal half-lives of the compounds between 3.0 and 5.2 h. 
Bioavailability following p.o. administration of 7 (13.3 mg/kg) was only 1%. In vitro permeability 
data obtained in Caco-2 cell monolayers (Table 1) demonstrated low permeability and high efflux 
ratios that are consistent with poor absorption in the gut. However, the high CL observed, which 
indicates high hepatic extraction, would also limit oral bioavailability of 7 and 8. 
In support of experiments aimed at testing the effects of compounds on tumour growth in mice, 
comparison of compound exposure following i.v. and intraperitoneal (i.p.) administration of 7 as a 
solution in 50% PEG E 400 indicated high bioavailability of 83% via the i.p. route at a dose of 
9.46 mg/kg (Table 2). Tmax was 0.083-0.25 h with a Cmax of 1333 ng/mL, equivalent to an unbound 
plasma concentration of 221 nM (Table 2). Administration of 8 at 9.69mg/kg via the i.p. route as a 
solution in 10% DMSO/50% solutol displayed a slightly higher Cmax (1647 ng/mL, equivalent to 
unbound 273 nM, assuming an unbound fraction equal to that of 7), similar tmax (0.083-0.25 h) 
(Table 2) but shorter half-life of 1.3 h (rat i.v. data, Table 2). Whilst the plasma concentration 
profiles of the racemic mixture (7) and active enantiomer (8) differed in these experiments (Figure 
S3), the difference is likely to have resulted from the suspension and solution formulations used, 
leading to slow and faster absorption, respectively, from the site of injection. Overall, these data 
demonstrate that concentrations of 7 and 8 can be attained via the i.p. route in mice that are 






Property Units species 7 8 
molecular weight Da - 525.65 525.65 
logD, pH 7.4 - - 1.58 1.59 







human 20.6±1.3 22.5±0.33 
Rat 13.6±1.2 16.4±1.32 





human 22.9±0.8 26.8±0.4 
Rat 17.6±0.3 17.6±0.4 
mouse 8.7±0.9 N.D. 
















2C9 34.15±1.01 >50 
2C19 26.19±0.5 >50 
2D6 3.64±1.5 1.6±0.15 
3A4 2.35±0.9 7.3±1.2 
hERG currents µM - >30 >30 
 
 
Table 1: ADME properties of lead compound 7 and 8 
 
hERG potassium channel currents were determined in quadruplicate, Caco-2 permeability, 
plasma protein binding, CYP inhibition and liver microsomal CLint in triplicate and solubility, logD, 








dose route Parameter 7 8 
Rat Pharmacokinetics 
i.v. 






terminal t½ (h) 3.0±2.0 5.2±0.07 
p.o. 
dose (mg/kg) 13.3 N.D. 
F (%) 1.0 N.D. 
Mouse Pharmacokinetics 




Vss (L/kg) 3.2±5.1 N.D. 
terminal t½ (h) 1.3±0.2 N.D. 
i.p. dose (mg/kg) 9.46 9.69 




unbound Cmax (nM) 221±28 273±37 
F (%) 83 N.D. 
 
Table 2: Pharmacokinetic characteristics of lead compounds 7 and 8 
Data are presented as mean ± SD for determinations in 3 animals. Bioavailability (F) was 






AM2 receptor antagonists inhibit pancreatic tumor growth in vitro and in vivo in mice 
As there are many well-documented pathological functions of AM and the AM2 receptor in cancer, 
we used cancer cell and animal models to characterize our lead compounds. A panel of human 
pancreatic cancer cells (AsPC-1, Capan-2, CFPAC-1, HPAF-II and Panc10.05) have been shown 
to express AM, CLR and RAMPs mRNA (Table S4). Lead AM2 receptor antagonists were 
subsequently tested on CFPAC-1 (which expressed AM, CLR and RAMP3 mRNA) to ascertain 
their effects on cancer cell viability and apoptosis in vitro. Lead compounds 7 and 8 were both 
able to decrease pancreatic cancer cell viability by up to 40% and 31% respectively, after 9 days 
of daily treatment at 3 µM concentration (Figure 3a, p<0.05). To control for CGRP receptor-
mediated effects, we treated cultures of CFPAC-1 cells with rimegepant, a highly selective CGRP 
antagonist (pIC50 = <5 for AM2 and 9.90 for CGRP receptors, Figure S4) and saw no significant 
reductions in viability (Figure 3a). 7 and 8 were also able to enhance levels of apoptosis markers 
(Caspases 3 and 7) in serum-starved pancreatic cancer cells by up to 50% and 104% 
respectively, 24 hours after treatment with varying concentrations between 3 μM and 100 nM 







Figure 3: Effect of AM2 receptor antagonists on in vitro viability and apoptosis of human 
pancreatic cancer cell line CFPAC-1 as well as subcutaneous CFPAC-1 tumor growth and 
survival in Balb/c nude mice. (a) Daily treatment with small molecule AM2 receptor antagonists 
significantly decreased viability of CFPAC-1 in a concentration-dependent manner (p<0.001). 
Viability was decreased by up to 42% after 6 days when treated with either antagonist, compared 
to vehicle-treated controls (p<0.001). 8 had significantly greater effect in decreasing viability of 
CFPAC-1, compared to 7 (p<0.001). Rimegepant did not affect CFPAC-1 viability at tested 
concentrations (3 and 10 µM). Data are from three independent experiments and presented as 
mean±SD. (b) Treatment with various concentrations of small molecule AM2 receptor antagonists 
significantly increased apoptosis of serum-starved (stressed) CFPAC-1 by up to 63% after 24 
hours, compared to vehicle-treated stressed controls (p<0.001). Data are from three independent 
experiments and presented as mean±SD. (c, d, e) Mice were inoculated with CFPAC-1 tumors and 
first treatment was given on the day of first tumor volume measurement (arrows). Tumor growth 
rates were significantly reduced in mice treated daily with 7 (c, p<0.001) or 8 (d, p<0.01). n=6-7 (c) 
or n=10 (d) mice per group (e) Kaplan-Meier survival curves showed daily treatment with 20 mg/kg 
8 significantly improved median survival to humane endpoint compared to vehicle-treated mice 
(29.5 vs. 21 days, p<0.001). Data presented as percentage of population. n=10 mice per group. 







In order to gain insights into the potential therapeutic index of these AM2 receptor antagonists, in 
vivo efficacy studies were conducted. 7 and 8 (20 mg/kg) or a vehicle control were administrated 
i.p. once daily, following the inoculation of tumor cells subcutaneously under the skin of the flank 
of Balb/c nude mice. Tumors were measured twice weekly to monitor the tumor growth and the 
well-being of the mice was assessed by measuring body weight and assessing appearance and 
behaviour. Both compounds were well tolerated and body weight increases were not significantly 
different in treatment and vehicle control groups. No adverse effects were observed from 
administration, and all mice behaved normally during the experiments, exhibiting apparently 
normal activity, feeding and inquisitiveness. 
Daily administration of 7 was associated with significant inhibition in pancreatic xenograft tumor 
growth of 56% at week 5 (p<0.001, Figure 3c). Similar results were observed upon administration 
of 8 (20 mg/kg) where after three weeks of treatment, there was significantly reduced growth of 
tumors by 44% in the 8-treated group (p<0.01, Figure 3d). While the experiments were not 
permitted to continue until the death of the animals from the tumors, we used as a surrogate for 
lifespan, the time taken for tumors to reach the local welfare regulatory authority (UK Home 
Office) maximum permitted size, at which the animals were euthanized.  By this measure, mice 
treated with 20 mg/kg 8 have increased surrogate survival rates compared with vehicle-treated 
mice (p<0.001, Figure 3e) where at 28 days, all the vehicle treated mice had been euthanized but 
half the 8-treated group were still alive. 
AM2 receptor antagonist inhibits proliferation, cancer-associated fibroblast expression 
and blood vasculature in pancreatic tumors in vivo in mice 
To determine the mechanisms for the observed in vivo tumor growth inhibition as a result of AM2 
antagonist treatment, histological analysis was performed on subcutaneous human CFPAC-1 
tumors from in vivo mice studies. Daily administration of 7 (20 mg/kg) was associated with 





fibroblasts (alpha smooth muscle actin, αSMA, p<0.01, Figure 4b) and blood vasculature (CD31, 
p<0.05, Figure 4c), compared to vehicle-treated tumors. 
 
 
Figure 4. Histological analysis of AM2 receptor antagonist treatment on in vivo 
subcutaneous CFPAC-1 tumor growth in Balb/c nude mice. (a-c) Daily treatment with 
compound 7 (20 mg/kg) significantly inhibited markers of proliferation (Ki67, p<0.01), cancer-
associated fibroblasts (αSMA, p<0.01) and blood vasculature (CD31, p<0.05) in CFPAC-1 
subcutaneous tumors. Data are presented as mean±SD. Representative images of control and 









Here, we show the development and characterization of new potent first-in-class AM2 receptor 
antagonists. The compounds we describe have very good selectivity over the AM1, amylin and 
calcitonin receptors. Our best compound to date (compound 7) shows also just under 10-fold 
selectivity over the CGRP receptor. These molecules will aid understanding and the ability to 
manipulate this heteromeric receptor system with molecular precision. Specifically, through our 
structure/knowledge-based drug modelling approach, with its basis on CGRP antagonists and 
their reported interactions with the CGRP receptor, we have been able to develop the first highly 
potent and selective AM2 receptor antagonists. These agents will allow significant new insights 
into the pharmacology of receptors combining the CLR with the 3 RAMPs because until now, the 
CGRP antagonists and anti-CGRP antibodies, less than fully characterized RAMP antibodies and 
non-selective peptide antagonists were the only tools available for such research.  
Our modelling was based upon the published crystal structures of the CLR/RAMP1 CGRP 
receptor and the CLR/RAMP2 AM1 receptor, with and without docked compounds. For our 
studies, despite the lack of a crystal structure for the CLR/RAMP3 AM2 receptor, we created a 
hybrid model combining crystal structure information from the CLR domains of the CGRP and 
AM1 receptors with a predicted structure for the RAMP3 domain. The model has been optimized 
slightly during the course of our work, as a result of hypothesis-testing compound generation to 
strengthen knowledge over uncertainties around specific domains. However, the model has 
proved to be of significant value in our design strategy and has allowed us to deliver the 
molecules that we report here.  With the recent publication of cryo-EM structures of the full 
RAMP/receptor complexes novel sites for antagonism may be identified 34, 35.     
Chemical synthesis of our compounds has not been completely straightforward, but during the 
course of our studies, problems have been solved to provide a robust high-yielding synthetic 
route. The route currently has 18 steps from inexpensive commercially available materials and is 





The biological screening assay we have used is based upon inhibition of AM-induced cAMP 
synthesis in an engineered cell expressing the target receptor (AM2 receptor for the first screen, 
and other receptors in response to their specific ligands for selectivity determinations). The major 
actions of AM are mediated predominantly via cAMP, so that it is unlikely we have missed 
compounds with effects mediated by other signalling mechanisms 51.   
Functional studies of our compounds show consistent effects in a range of cancer model systems 
and across species (human, mouse and dog). Native cancer cells exhibit the same pharmacology 
as our engineered screening cells, with almost identical pIC50 values and the same preferential 
sensitivity to the stereoisomer 8 over 9.  Differences in pharmacology were shown across the 
species used with both compounds 7 and 8 showing lower efficacy on mouse and dog cells 
compared with human. However, it is unclear whether the observed pharmacological differences 
are due to differences between species or receptor expression. The in vitro cancer cell models 
comprise ways to measure cell viability and apoptosis (programmed cell death), both accepted in 
vitro markers of anti-tumor cell activity.  The ADME and PK properties of 8 and 7 were found to 
suitable for in vivo studies in mice, such that i.p. administration at approximately 10mg/kg 
provided unbound plasma concentrations several fold higher than their in vitro AM2 IC50 values. 
The effects of 8 (and the racemic mixture 7) in vivo are clear, and are associated with what would 
be valuable likely increases in lifespan if replicated in human clinical patients. As these 
compounds have only ~10-fold selectivity over CGRP receptors, it was important to determine 
whether the effects we saw were due to antagonism of AM2 or CGRP receptors. Use of the highly 
selective CGRP antagonist rimegepant (pIC50 = <5 for AM2 and 9.90 for CGRP receptors), which 
is effectively incapable of blocking AM2 receptors, revealed no inhibition of pancreatic tumor cell 
viability. Further clarification of this could be achieved by in vitro and in vivo xenograft studies 
using cells lacking either CGRP or AM2 receptors and treated with AM2 antagonists  
One feature of our studies could suggest that effects of AM2 antagonists in our mouse xenograft 





AM2 receptor and in the animal models they act on intrinsic signalling in the human tumor cells of 
the xenografts. However, tumor-secreted AM also acts on host cells in the tumor 
microenvironment as key RAMP residues in peptide-binding sites are conserved across many 
species including mouse30. On mouse cells (responding to AM expressed by the human tumor 
cells), our compounds are 2- to 100-fold less potent than on human cells. CGRP antagonists 
have historically shown even lower affinity in other species (including rodent and canine) 
compared to primates 52, 53. If tumor-host interactions mediated by AM are an important feature of 
some clinical patient groups, then our compounds could provide more potent inhibitory effects 
than seen in mice by the increased potency on the human host AM2 receptors. The lack of 
detectable side-effects in our studies are consistent with data showing that RAMP3 knockout 
mice (which are unable to make AM2 receptors) are viable and healthy 19, and that in humans, an 
inactivating single nucleotide polymorphism in the gene for RAMP3 is represented in populations 
of healthy women 28. 
In vitro effect of AM2 receptor antagonists on cancer cell viability and apoptosis are significant but 
modest, compared to their potency in cAMP inhibition and the effect on in vivo tumor growth. The 
data suggest that AM may not be the main driver of cancer cell proliferation or apoptosis evasion, 
but instead, the creation of a pro-tumoral microenvironment. Models used in drug discovery for 
oncology all have limitations and provide somewhat simplistic answers to the major question of 
whether a candidate molecule could work in human clinical disease. 
Histological analysis of tumor tissues revealed that anti-tumor effect of AM2 receptor antagonists 
are not confined to tumor cells, but also stromal components of the tumor microenvironment 
including cancer-associated fibroblasts and blood vasculature originating from host non-tumor 
cells. This is an important property as 90% of pancreatic tumor mass is composed of fibrous 
desmoplastic stroma which impedes delivery of therapeutic agents to pancreatic cancer cells 
within the dense tumor 54. Dai and colleagues have shown using in vivo gene knockout 





pancreatic tumor metastasis resulting from recruitment of cancer-associated fibroblasts 45. 
Additionally, AM has also been shown to mediate desmoplasia in pancreatic cancer by mediating 
the effect of MYB on pancreatic cancer cells and cancer-associated fibroblasts both in vitro and in 
vivo 55.  
Taken together, our data exemplify the strength of a rational drug design process to develop 
specific new antagonist molecules when sufficient structural information exists on targets, and 
there is access to a strong focused chemical starting point. We anticipate that our lead 
compounds will be the basis for improved molecules that will prove suitable in increasing 
understanding of fundamentals of the endocrinology of heteromeric receptors and as drug 
















Materials and Methods 
All reagents, unless otherwise stated, were obtained from commercial sources and used without 
further purification. Olcegepant, telcagepant, rimegepant and MK-3207 were purchased from 
MedChemExpress (MCE) and were reconfirmed for its activity. Details are available in Supporting 
information. Small molecule antagonists were prepared as 2 mM DMSO stocks for cell culture 
experiments and stored at -20°C. Based on each cell lines ligand-receptor combination the 
appropriate unlabelled peptide was used. Human CGRP was obtained from Sigma Aldrich 
(SCP0060), rat AMY (rAMY) and human calcitonin (hCTR) were purchased from Bachem (H-
9475 and H-2250 respectively) and human AM was purchased from Anaspec (AS-60447). 
Compound synthesis and characterization 
Compounds synthesis and characterization data are included in Supporting Information page S6. 
Modelling and docking 
Modelling and docking information are included in Supporting Information page S27 
Cell lines and culture conditions 
All cell lines were purchased from ATCC, Cell Applications, Inc or DiscoverX with proof of 
authentication, unless stated. All cell lines were maintained at 37°C in a humidified atmosphere 
with 5% CO2. Human pancreatic cancer cells CFPAC-1 (ATCC, CRL-1918) were cultured in 
Dulbecco's Modified Eagle Medium (DMEM, Thermo Fisher Scientific, 61965-026) containing 
10% (v/v) fetal bovine serum (FBS, Thermo Fisher Scientific, 10500-064) and 1% (v/v) penicillin–
streptomycin (Sigma Aldrich, P4333). Canine aortic endothelia (CnAOEC) cells (Cell Applications, 
Cn304-05) were cultured in Canine EC Growth Medium Kit (Cell Applications, Cn211K-500). 
Mouse prostate cancer cells 178-2 BMA was obtained from Dr Timothy C. Thompson from the 
University of Texas MD Anderson Cancer Centre56. These cells were cultured in Dulbecco's 
Modified Eagle Medium (DMEM, Thermo Fisher Scientific, 61965-026) containing 10% (v/v) fetal 





streptomycin (Sigma Aldrich, P4333). CGRP receptor, AM1 receptor, AM2 receptor, AMY1 
receptor, AMY3 receptor and CTR overexpressing cell lines were obtained from DiscoverX 
(catalogue numbers, culture and selection information in Table S5). The RAMP/receptor 
component expression of these cells were validated in-house (Table S7). 
Time-resolved fluorescence resonance energy transfer (TR-FRET) cAMP accumulation 
The functional properties of compounds in GPCR/RAMP overexpressing cells (i.e. AM2, CGRP, 
AM1, AMY1 and AMY3 cells) as well as in human pancreatic cancer cells (CFPAC-1), in canine 
aortic endothelia (CnAOEC) cells and in mouse prostate cancer cells (178-2 BMA) were 
evaluated for their ability to inhibit cAMP production induced by an EC50 concentration of the 
maximum agonist activation (concentrations for each overexpressing cell line can be found in 
figure S5, table S6 and table S8 for the naïve cells). . Each compound was tested at 8 full-log 
concentrations (10−11 to 10−5 M) including a negative control (blank). The total cAMP was 
measured using the TR-FRET LANCE cAMP detection kit (PerkinElmer, AD0264), according to 
the manufacturer’s directions. Aliquots of frozen cells (2 × 106 each) were thawed and prepared in 
warm stimulation buffer (1 × HBSS, 5 mM HEPES, 0.5 mM IBMX, and 0.1% BSA). Alexa Fluor 
antibody (1:100 concentration) was then added to the cell suspension and cells were plated 
(2,500 cells, 6 μL) in a 384-well white opaque microtiter plate (OptiPlates, Perkin Elmer, 
6007299). Cells were first pre-incubated with serial dilutions (3 μL) of the antagonists for 30 
minutes at room temperature prior to their stimulation with the EC50 value of agonist (3 μL) for 15 
minutes at room temperature. Subsequently, 12 µL detection mix (Europium-Chelate 
streptavidin/biotinylated cAMP) was added to stop the reaction and induce cell lysis. TR-FRET 
was detected after an hour incubation by an EnSight multimode Plate reader (Perkin Elmer), at; 
320/340 nm excitation and 615/665nm emission. Data were normalized to agonist only and blank 
(stimulation buffer only) wells as 0% and 100% cAMP inhibition, respectively.  
The final DMSO concentration was below 0.5% and this was kept consistent in all the wells, 





used for all cell lines. Concentration-response curves were analysed using three-parameter 
logistic curve to determine IC50 values (Graphpad Prism 7 and 8). No further constrains in any 
parameters of the curves were used.  
In vitro viability and apoptosis assays 
RealTime-Glo MT Viability Assay 
Cell viability in human pancreatic cancer cells (CFPAC-1) was quantified using RealTime-Glo MT 
Cell Viability Assay (Promega, G9712). Cells (2,000 cells) were seeded into 96-well white clear-
bottom plates (Corning, 3903) in full serum media overnight before washing and changing to sub-
optimal media (DMEM + 5% FBS + 1% P/S) containing RealTime-Glo™ reagents according to 
Promega protocol. A baseline luminescence read (prior to treatment) was taken using EnSight 
Multimode Plate Reader (PerkinElmer) after an hour of incubation at 37°C. Cells were then 
treated with compounds or vehicle-control (PBS + 0.05% DMSO) daily. Results were normalized 
to vehicle-treated controls as 100% viable (Graphpad Prism 7 and 8). 
Caspase-Glo 3/7 Apoptosis Assay 
The effect of the compounds on cell apoptosis in human pancreatic cancer cells (CFPAC-1), was 
determined using luminescence-based Caspase-Glo™ 3/7 Assay (Promega, G8093). This end-
point assay measures late-stage apoptotic markers – caspases 3 and 7. Cells (20,000 cells) were 
seeded into 96-well white clear-bottom plates (Corning, 3903) Cells were then treated for 24 
hours with compounds (or vehicle-control) diluted in PBS (0.05% DMSO). Caspase-Glo™ 
reagent was prepared according to Promega protocol and added to the cells. Each sample was 
incubate for 30 to 60 minutes on a plate shaker (550 rpm). Luminescence read was then taken 
using EnSight Multimode Plate Reader (PerkinElmer) set to 22°C. Baseline readings (media only) 
were subtracted from sample luminescence readings. Results were normalized to unstressed 
controls (optimal growth media) and serum-starved vehicle controls as 0% and 100% apoptosis, 





ADME and physicochemical assays 
Kinetic solubility 
Compounds initially dissolved at a concentration of 10 mM in DMSO were diluted in 50 mM 
phosphate buffer (pH 2 or 7.4) to a concentration of 200 μM, followed by vigorous shaking for 24 
h at room temperature. Precipitated material was then removed by filtration and the remaining 
compound concentration was established using UV absorbance. 
Microsomal stability assays 
Metabolic stability of compounds was assessed in the presence of human (Corning, 452117), rat 
(Xenotech, R1000) or mouse (Xenotech,M1000) microsome suspensions in 100 mM potassium 
phosphate buffer at a protein concentration of 0.5 mg/ml. 10 μL of a solution of 10 μM of each 
test compound or positive controls (testosterone, diclofenac and propafenone) were added into 
the appropriate wells of 96-well plates (a matrix blank was also included). 80 μL of microsomal 
suspension was added to test compound followed by incubation for 10 min at 37°C. Reactions 
were initiated by addition of 10 μL of pre-warmed NADPH (β-Nicotinamide adenine dinucleotide 
phosphate) and plates were incubated at 37oC. Reactions were stopped after 60, 30, 20, 10, 5 
and 0 min by the addition of 300 μL/well of cold (4oC) stop solution (100 ng/mL tolbutamide and 
100 ng/mL labetalol). Sample plates were then shaken for 10 minutes followed by centrifugation 
at 4000 rpm for 20 min at 4oC. Rates of decrease in compound over time were determined using 
LC-MS/MS and microsomal intrinsic clearance (CLint) was then calculated. 
Plasma stability assays 
A known concentration of compound (0.1-1 μM) was incubated in the presence of human 
(BioIVT, HMPLEDTA2), rat (BioIVT, RATPLEDTA2-M) or mouse (BioIVT, MSE00PLK2M2N) 
plasma (80% in PBS, pH 7.4) for up to 120 min (0, 5, 15, 30, 60, 120 min). Propantheline bromide 
was used as reference compound. At the end of each time point the % of the remaining 





Plasma Protein Binding (PPB) assays 
PPB was determined using an equilibrium dialysis assay in which a semi-permeable membrane 
separates two compartments, one of which contains undiluted plasma containing added test 
compound (2 µM) and the other containing buffer (Dialysis Buffer -100 mM sodium phosphate 
and 150 mM NaCl, pH 7.4 ± 0.1). The system is then incubated at 37°C until equilibrium was 
reached (5% CO2 at 37±1°C for 4 hours and the amount of test compound in each compartment  
was then  (Fu)MS/MS. The fraction of unbound compound -using LC was then analysed
calculated using the relationship Fu = concentration in buffer/ concentration in plasma. Known 
control compounds, including verapamil and warfarin, were used for assay validation. 
Cytochrome P450 (CYP450) enzymes inhibition assays 
Five different cytochrome P450 isoforms (1A2, 2C9, 2C19, 2D6 and 3A4) were investigated with 
cytochrome P450 enzyme inhibition assays. Specific substrates (Table S9) for each isoform were 
incubated with a range of test compound concentrations (0-50μM) in the presence of human liver 
microsomes. At the end of the incubation, the formation of a known metabolite depending on the 
isoform was monitored using LC-MS/MS. The ability (IC50) of each test compound to inhibit the 
formation of the metabolites was then measured compared to the vehicle control. Known positive 
inhibitors of each isoform were also used for assay validation (Table S9). 
hERG channel test 
To evaluate the effects of test compounds on the hERG potassium channels, the automated 
patch clamp method (QPatchHTX) was used. CHO cells stably expressing hERG potassium 
channels (Aviva Biosciences) were used for this test at 75% confluency or more. Before testing, 
cells were harvested using TrypLE and resuspended in the extracellular solution at the room 
temperature. All solutions used for the electrophysiological recordings are shown in Table S10.  
Test compounds and positive control (Amitriptyline) were dissolved in 100% DMSO to obtain 





extracellular solution to achieve final concentrations for testing (final DMSO concentration not 
more than 0.3%). 
Voltage command protocol: From the holding potential of -80 mV, the voltage was first stepped 
to -50 mV for 80 ms for leak subtraction, and then stepped to +20 mV for 4800 ms to open hERG 
channels. After that, the voltage was stepped back down to -50 mV for 5000 ms, causing a 
"rebound" or tail current, which was measured and collected for data analysis. Finally, the voltage 
was stepped back to the holding potential (-80 mV, 3100 ms). This voltage command protocol 
was repeated every 15000 msec. This command protocol was performed continuously during the 
test (vehicle control and test compound). 
QPatchHTX Whole-cell recording: hERG QPatchHTX assay was conducted at room temperature. 
All protocols were established and performed using QPatch Assay Software 5.6 (Sophion 
Bioscience). Three additions of 5 µl of the vehicle were applied, followed by 30 runs of voltage 
protocol for a baseline period. Then the ascending concentrations of each compound were added 
with three repetitions (5 µl*3). The exposure of test compound at each concentration was no less 
than 5 minutes. Five concentrations (0.37 µM, 1.11 µM, 3.33 µM, 10 µM and 30 µM) were tested 
for each compound (minimum 2 replicates per concentration). 
Within each well recording, percent of control values were calculated for each test compound 
concentration current response based on peak current in presence of vehicle control. Curve-fitting 
and IC50 calculations were performed by QPatch Assay Software. If the inhibition obtained at the 
lowest concentration tested was over 50%, or at the highest concentration tested was less than 
50%, we reported the IC50 as less than lowest concentration, or higher than highest 
concentration, respectively. 
Ethical statement for in vivo studies 
All in vivo experiments were performed according to the regulations of the UK Animals (Scientific 





committees through the granting of project and personal licenses for the studies. Where studies 
were performed outside of the UK and not directly under those mandatory legal constraints, 
methodology and conditions were approved before the studies by the National Council for the 
3Rs (Reduction, Refinement and Replacement) and the Wellcome Trust. 
Pharmacokinetic (PK) studies 
PK studies were performed in mice and rats using i.v., p.o. and i.p. routes of administration. Each 
mouse study was performed using 3 male (7-9 weeks old) CD-1 mice (source: WTLH Laboratory 
Animal Co. Ltd. or SIPPR-B&K Laboratory Animal Co. Ltd.). Rat PK studies were performed 
using 3 male (7-9 weeks old) Sprague Dawley (SD) rats (source: SLAC Laboratory Animal Co. 
Ltd. or WTLH Laboratory Animal Co. Ltd.). Compounds were accurately weighed and dissolved in 
the appropriate volume of vehicle (50% PEG E 400/50% water or 10% DMSO/50% Solutol/40% 
water). The solution was sonicated in a water bath until clear solution (i.v and i.p dosing) and 
uniform suspension (p.o dosing) was obtained, pH adjusted if needed and sterile filtered prior to 
administration. For i.v dosing, the compounds were administered via tail vein following the 
facility’s SOPs. For oral dosing (p.o) compounds were administered by oral gavage. For i.p 
dosing the compounds were injected in the animal’s lower right quadrant of the abdomen 
following the facility’s SOPs. The dose volume was determined by the animals’ body weight 
collected on the morning of dosing day.  
At different time points after administration, approximately 0.25 mL (in rats) and 30μL (in mice) of 
blood was collected from each animal (via jugular vein or another suitable vein - in rats via the 
saphenous vein or in mice, the submandbular vein). At each time point, the animals were 
restrained and the blood sample was taken using a needle and while observing aseptic 
precautions. Samples were transferred into ice cold microcentrifuge tubes containing 5 μL of anti-
coagulant (0.5 M EDTA-K2). Samples were then centrifuged at 3,000 g at 4oC for 15 min. Plasma 





LC-MS/MS analysis. Upon completion of the studies animals were euthanised using Carbon 
dioxide (CO2) overdose (Carbon Dioxide Euthanasia). 
In vivo efficacy models 
In these studies, we used 6-7 week old BALB/c nude female mice, with a weight range of 15-20g. 
Animals were provided by Envigo Corporation (Cambridgeshire, UK) or Charles River 
Laboratories (Massachusetts, USA) depending on availability. Each experiment started with 10 
mice (experimental units) in each experimental/control group. Subsequent analysis (tumor growth 
and histology) was only performed in animals where tumors had established and were palpable 
within 3 days of implantation. This was in accordance with power calculation performed to ensure 
robust statistical analysis by The University of Sheffield Statistical Service. Implanting cells into 
10 animals in each group ensured that we had a minimum of 6 mice completing the procedure in 
all our studies. Where tumors established in more than 6 mice, all were included for data 
analysis. The animals were housed in individually ventilated cages (IVCs) (with the appropriate 
bedding and flooring conditions) in environmentally controlled conditions with a 12 hr light/dark 
cycles at ~26°C. Mice had access to adequate amount of water and 2018 Teklad Global 18% 
Protein Rodent Diet containing 1.01% Calcium (Harlan Laboratories, UK). The day-to-day care of 
the animals was carried out by the technicians in the Biological Services (The University of 
Sheffield, UK). All scientific procedures on animals were carried under UK Home Office Project 
Licenses (40/3499 or PF61050A3) and Procedure Individual Licenses. 
Compound preparation for in vivo studies 
Compounds were dissolved in DMSO (Sigma Aldrich, D4540) and sonicated at 37°C for 10 mins. 
Appropriate volume of solvent (Kolliphor HS15 (1 part, grams), Kollisolv PEG E 400 (3 parts, mL) 
and PBS (6 parts, mL)) was then added to yield a 6% DMSO/94% solvent solution. These 
working stocks (8 mg/mL) were further sonicated at 37°C for 10 mins before storing at -20oC. To 
make treatment aliquots, equal amounts of the working stock (or vehicle-control) and solvent 





solvent). Vehicle-control and compounds were sonicated at 37°C for 10 mins prior to i.p. 
injections (200 µL per mouse). 
Cell preparation and tumor inoculation 
Cells were prepared according to standard cell culture techniques. Cell pellets were resuspended 
in 50% PBS/50% Matrigel (Corning, 354234). Matrigel/PBS cell suspension, needles (25G) and 
syringes (1 mL) were kept on ice before and during tumor inoculation into mice. Cell suspension 
(100 µL, 5 × 106 cells) was injected subcutaneously into the left flank of 6-7 weeks old female 
immunodeficient nude athymic mice (Balb/c nude). Once the tumors became palpable (around 
100 mm3), mice were randomized into treatment groups. Mice were treated daily by i.p. injection 
at the same time of day with 20 mg/kg of compound or vehicle-control (200 µL per mouse) until 
humane end-point. Mice were observed for at least 30 mins post-treatment to detect any acute 
adverse effects. Tumor size and mouse weights were measured twice a week. At the end of each 
study the animals were euthanized following the appropriate procedures listed in ASPA Act 1986. 
Vital organs and tumors were stored in 10% neutral-buffered formalin for further histological 
analysis. Primary experimental outcome was tumor volume with additional measurement of 
molecular markers in tissue and serum as well as time to humane endpoint. Blinding was not 
used for the in vivo studies. 
Immunohistochemistry (IHC) 
Immunohistochemical detection of CD31 (Dianova, DIA-310), Ki67 (Abcam, ab15580) and αSMA 
(Abcam, ab124964) was performed in paraffin-embedded tumor sections obtained from the in 
vivo studies using ABC system (Vector Laboratories). All stained slides were scanned using 
Panoramic 250 Flash III slide scanner (3DHISTECH). Specific protocols used can be found in 
Table S11. Sections were dewaxed in a graded xylene/ethanol series and antigens were 
retrieved by incubating the slides in Tris-EDTA (TE) buffer (Fisher Scientific) for 20 minutes using 
a conventional food steamer (for Ki67) or by incubating the slides in a 95°C PT module (Thermo 





Endogenous peroxidase was then blocked by incubating slides in 3%H2O2 (Sigma-Aldrich) in 
distilled H2O for 30 minutes at RT. Slides were then blocked with 1.5% blocking serum (ABC 
VECTASTAIN IgG Kit) and incubated with the primary antibody (concentrations can be found in 
Table S11) at 4°C overnight (1 hour at RT for Ki67). After successive incubations (30 minutes at 
RT) with the corresponding biotinylated IgG (Vector Laboratories) and the ABC solution (Vector 
Laboratories), the peroxidase activity was developed using 3, 3'-Diaminobenzidine (DAB) 
(ImmPACT™ DAB EqV) as a substrate. Slides were counterstained with Gill’s hematoxylin 
(Merck) for 20 seconds, dehydrated, and mounted with coverslips using DPX (distyrene, 
plasticizer and xylene mixture) mounting medium (Sigma-Aldrich).  
Immunohistochemistry (IHC) analysis 
QuPath v0.1.2, an open source digital pathology software was used to identify and count the 
positive cells (brown) in Ki67 stained sections.  The whole tumor sections were selected as 
regions of interest (ROIs) and the positive cell detection command was performed, using the 
single threshold option, to distinguish and quantify the brown stained (positive) cells from the 
negative hematoxylin (blue) stained cells. For the αSMA stained sections ImageJ v1.49 was used 
for analysis. The whole tumor sections were selected as regions of interest (ROIs). Using the 
colour threshold tool, brown DAB (positive) staining was highlighted while all blue hematoxylin 
(negative) stained sections were excluded. Masks of the highlighted regions were then generated 
and were used to measure the percentage area of positive staining. Similarly, the same 
procedure was used for the analysis of CD31 sections however, only four snapshots (ROIs) per 
slide were used due to the low intensity of the CD31 staining. 
Statistics 
For cAMP accumulation studies all data consist of at least three independent experimental 
repeats. Each independent experimental repeat is performed on a new batch of cells and on a 
separate date from the previous repeat. Curves shown are representative and do not include all 





by unpaired t-test. Student’s t-test or one-way ANOVA were used to compare between groups of 
one experimental variable. In experiments where there are more than one experimental variable, 
two-way ANOVA was used to analyse individual variables and the interaction between them. 
Repeated-measures two-way ANOVA was used to analyse time course data and normalised data 
(e.g. viability and apoptosis data). Post-hoc multiple comparisons tests (Dunnett or Tukey) were 
also used to determine statistical significance of differences. Log-rank test was used to compare 
Kaplan-Meier survival curves. 
Data availability   
All data generated or analysed during this study are either included in this published article (and 
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Brief synopsis: Graphic showing the docking of lead compound 8 in AM2R hybrid model and its 
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